.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,104,470

« Back to Dashboard
Patent 7,104,470 protects STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, COMBIVENT RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.

This patent has fifty-eight patent family members in thirty-four countries.

Summary for Patent: 7,104,470

Title:Device for producing high pressure in a fluid in miniature
Abstract: A miniaturized device for pressurizing fluid. The device includes a hollow piston that provides a fluid path and a valve member. The valve member is configured for axial movement so that the valve axis remains parallel to the piston axis. The valve member is arranged at one end of the hollow piston. The valve member may be partially or completely disposed within the hollow piston. The device is particularly adapted for use in a mechanically operated atomizer to produce an inhalable aerosol of a liquid medicament without the use of propellant gas.
Inventor(s): Jaeger; Joachim (Bruchsal, DE), Cirillo; Pasquale (Dortmund, DE), Eicher; Joachim (Dortmund, DE), Geser; Johannes (Dortmund, DE), Freund; Bernhard (Gau-Algesheim, DE), Zierenberg; Bernd (Bingen am Rhein, DE)
Assignee: Boehringer Ingelheim International GmbH (DE)
Application Number:11/165,496
Patent Claim Types:
see list of patent claims
Device; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Chemical engineering
Back Citations: 100th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYes7,104,470► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXNo7,104,470► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYes7,104,470► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,104,470

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
GermanyP195 36 902Oct 04, 1995

Non-Orange Book Patents for Patent: 7,104,470

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,918,547 Device for producing high pressure in a fluid in miniature► subscribe
5,964,416 Device for producing high pressure in a fluid in miniature► subscribe
6,402,055 Device for producing high pressure in a fluid in miniature► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,104,470

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina003794► subscribe
Austria248028► subscribe
Austria352379► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc